Transaction #3312 · Form 4 · 0001493152-25-020221
Cocrystal Pharma, Inc. · Stock award · Warrants
Cocrystal Pharma, Inc. · Transacted October 28, 2025 · Filed October 30, 2025
What does this filing report?
An SEC Form 4 filing for Cocrystal Pharma, Inc. records a stock award involving Warrants on October 28, 2025. The reported quantity was 719,426. The filing date is October 30, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Cocrystal Pharma, Inc.
- Company CIK
- 0001412486
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 719,426
- Reported price
- 1.39
- Reference value
- 1,000,002.14
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 719,426
- Ownership description
- Not reported
- SEC acceptance time
- Oct 30, 2025, 4:15 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Hassan Fred ↗
Director
CIK 0001110744
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 719,426
- Conversion / exercise price
- 1.24
- Exercise date
- Not reported
- Expiration date
- January 28, 2028
Filing footnotes & remarks
- F1
- The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.
- F2
- Includes shares of common stock issuable upon vesting of restricted stock units.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.